•utilizing our superior mapping technology and open platform to establish our presence withwithin a broadgeographically targeted base of customer accounts and physicians;

•strategically expandingpositioning our commercial organization across key global marketstargeted geographic regions to increase physician awareness and drive adoption;

driving market penetration•maximizing console utilization and portfolio utilization;

•continuing to strategically expand our portfolio of products and broaden indications for existing products;

•leveraging our strategic partnerships to efficiently scale globally and broaden our product portfolio; and

•continuing to build our clinical evidence base.

•significantly greater name recognition;

•broader or deeper relations with healthcare professionals, customers and third-party payors;

•greater experience in conducting research and development, manufacturing, clinical trials, marketing and obtaining regulatory clearance or approval for products; and

•greater financial and human resources for product development, sales and marketing and patent prosecution.

continue to•strategically develop innovative proprietary products that address significant clinical needs in a manner that is safe and effective for patients and easy-to-use for physicians;

•obtain and maintain regulatory clearances or approvals;

•demonstrate safety and effectiveness in our sponsored and third-party clinical trials;

•expand our sales force acrosswithin key marketsgeographic regions to increase physician awareness;

•leverage our strategic partnerships and alliances to achieve distribution at a global scale and broaden our product portfolio and enable and accelerate global connectivity;

•obtain and maintain coverage and adequate reimbursement for procedures using our products;

•attract and retain skilled research, development, sales and clinical personnel;

•cost-effectively manufacture, market and sell our products; and

•obtain, maintain, enforce and defend our intellectual property rights and operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others.

•the FDA’s QSR, which requires manufacturers, including their suppliers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;

•labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses;

•medical device reporting, or MDR, regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur;

•medical device recalls, which require that manufacturers report to the FDA any recall of a medical device, provided the recall was initiated to either reduce a risk to health posed by the device or to remedy a violation of the FDCA caused by the device that may present a risk to health; and

•post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device.

•warning letters, fines, injunctions, consent decrees and civil penalties;

•repair, replacement, refunds, recall or seizure of our products;

•operating restrictions, partial suspension or total shutdown of production;

•refusing our requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products;

•withdrawing 510(k) clearance or premarket approvals that have already been granted; and

•criminal prosecution.

•registration of medical devices in individual EEA countries;

•field safety corrective actions, including product recalls and withdrawals; and

•interactions with physicians.

Accountable•Accountable to patients, physicians and each other;

Courageously•Courageously pursuing continuous improvement;

United•United as one team achieving excellence;

Science•Science based-talent driven.

•long-standing relationships with competing companies and distributors that sell other products;

•competitive responseresponses and negative selling efforts from providers of alternative products;

•lack of experience with our products and concerns that we are relatively new to market;

•lack or perceived lack of sufficient clinical evidence, including long-term data, supporting safety or clinical benefits; and

•time commitment and skill development that may be required to gain familiarity and proficiency with our products.

•changes in a country’s or region’s political or economic conditions, including any potential impact resulting from the U.K.’sUnited Kingdom’s, or UK, exit from the European Union, commonly referred to as Brexit;

•untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;

•customer notifications for repair, replacement or refunds;

•recall, detention or seizure of our products;

•operating restrictions or partial suspension or total shutdown of production;

•withdrawing 510(k) clearances or PMA approvals that have already been granted;

•refusal to grant export approval for our products; or

•criminal prosecution.

strengthen•strengthens the rules on placing devices on the market and reinforcereinforces surveillance once they are available;

establish•establishes explicit provisions on manufacturers’ responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;

improve•improves the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;

set•sets up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the European Union; and

strengthen•strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.

•the Anti-Kickback Statute, which prohibits, among other things, knowingly and willingly soliciting, offering, receiving or paying remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual, or the purchase, order or recommendation of items or services for which payment may be made, in whole or in part, under a federal healthcare program such as the Medicare and Medicaid programs. The term “remuneration” has been broadly interpreted to include anything of value, and the government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of the law or a specific intent to violate. In addition, the government may assert that a claim, including items or services resulting from a violation of the Anti-Kickback Statute, constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. The Anti-Kickback Statute is subject to evolving interpretations and has been applied by government enforcement officials to a number of common business arrangements in the medical device industry. There are a number of statutory exceptions and regulatory safe harbors protecting certain business arrangements from prosecution under the Anti-Kickback Statute; however, those exceptions and safe harbors are drawn narrowly, and there may be limited or no exception or safe harbor for many common business activities such as reimbursement support programs, educational and research grants or charitable donations. Practices that involve remuneration to those who prescribe, purchase or recommend medical devices, including discounts, providing items or services for free or engaging such individuals as consultants, advisors or speakers, may be subject to scrutiny if they do not fit squarely within an exception or safe harbor and would be subject to a facts and circumstances analysis to determine compliance with the Anti-Kickback Statute. Our practices, such as trial periods or purchase of certain components of our mapping systems from customers, may not in all cases meet all of the criteria for statutory exception or regulatory safe harbor protection from anti-kickback liability. In October 2019, the federal government published two proposed regulationsCMS issued a final rule effective January 19, 2021 that would createcreated new safe harbors for, (amongamong other things)things, certain value-based arrangements and patient engagement tools that modified and modify and clarifyclarified the scope of existing safe harbors for warranties and personal service agreements; even if these regulations are eventually finalized, theagreements.The impact of the proposednew safe harbor regulations on our operations is not yet clear.

•actual or anticipated changes or fluctuations in our operating results;

•the failure by our customers to obtain coverage andat reimbursement levels that would be sufficient to support product sales to our customers;

•unanticipated serious safety concerns related to the use of our products;

•the financial projections we may provide to the public, and any changes in these projections or our failure to meet these projections;

•announcements by us or our competitors of new products, significant acquisitions, strategic partnerships, joint venture, capital commitments or capital commitments;

•industry or financial analyst or investor reaction to our press releases, and other public announcements and filings with the SEC;

•rumors and market speculation involving us or other companies in our industry;

•future sales or expected future sales of our common stock;

•price and volume fluctuations in the overall stock market from time to time;

•changes in operating performance and stock market valuations of other medical device companies generally, or those in our industry in particular;

•our cash position;

the expiration of market stand-off or contractual lock-up agreements and •sales of shares of our common stock by us or our shareholders;

•failure of industry or financial analysts to maintain coverage of us, changes in financial estimates by any analysts who follow our company or our failure to meet these estimates or the expectations of investors;

•actual or anticipated developments in our business or our competitors’ businesses or the competitive landscape generally;

•our inability to obtain adequate supplies and components for our products or inability to do so at acceptable prices;

•litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;

•accusations that we have violated a law or regulation;

•recalls of our products;

•developments or disputes concerning our intellectual property rights, our solutions or third-party proprietary rights;

•any delay in any regulatory filings for our planned or future products and any adverse development or perceived adverse development with respect to the applicable regulatory authority’s review of such products;

•changes in laws or regulations applicable to our products;

•breaches of, or failures relating to, security, privacy or data protection;

•new laws or regulations or new interpretations of existing laws or regulations applicable to our business;

•any major changes in our management or our board of directors;

•changes in accounting principles;

•ineffectiveness of our internal controls;

•actual or anticipated changes in healthcare policy and reimbursement levels;

•general economic conditions including increased inflation and slow or negative growth of our markets; and

•other events or factors including those resulting from war, incidents of terrorism or responses to these events.

not being required to have•no requirement for our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act;

•reduced disclosure obligations regarding executive compensation in our periodic reports and Annual Report on Form 10-K; and

•exemptions from the requirements of holding non-binding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.

•the last day of the fiscal year in which we have more than $1.07$1.235 billion in annual revenue;

•the last dateday of the fiscal year in which we qualify as a “large accelerated filer,” with at least $700 million of equity securities held by non-affiliates;

•the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; or

•December 31, 2025, the last day of the fiscal year ending after the fifth anniversary of the completion of our initial public offering or IPO.

•delaying, deferring or preventing a change in corporate control;

•impeding a merger, consolidation, takeover or other business combination involving us; or

•discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.

•establish a classified board of directors so that not all members of our board of directors are elected at one time

•authorize the issuance of “blank check” preferred stock that our board of directors could use to implement a stockholder rights plan;

•permit the board of directors to establish the number of directors and fill any vacancies and newly-created directorships;

•provide that directors may only be removed for cause;

•require super-majority voting to amend some provisions in our certificate of incorporation and bylaws;

•eliminate the ability of our stockholders to call special meetings of stockholders;

•prohibit stockholder action by written consent, which requiresthereby requiring all stockholder actions to be taken at a meeting of our stockholders;

•provide that the board of directors is expressly authorized to make, alter or repeal our bylaws;

•restrict the forum for certain litigation against us to Delaware; and

•establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.

•any derivative action or proceeding brought on our behalf;

•any action asserting a claim of breach of fiduciary duty;

•any action asserting a claim against us arising under the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; and

•any action asserting a claim against us that is governed by the internal-affairs doctrine.